The role of surgery for malignant pleural mesothelioma encompasses the need for rapid diagnosis, preoperative staging and surgical resection, and also the need for a greater biological understanding ...

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer ...

SMART combines high-dose IMRT with extrapleural pneumonectomy, showing improved survival for malignant pleural mesothelioma patients. The trial demonstrated a median overall survival of 24.4 months, ...

The MARS2 trial put the mesothelioma treatment community off its axis, at least in terms of whether these patients should undergo surgery. The phase III study showed that extended pleurectomy ...

Chemical pleurodesis. The surgeon puts a chemical, usually talc, into the pleural space (the space between your lungs and your chest wall.)‌ Mechanical pleurodesis. The surgeon abrades (brushes) the ...

Researchers have developed a new method for filling and sealing pleural cavities. The process consists of injecting polyurethane foams into the lungs with a self-expanding and self-modelling capacity ...

Although surgery can prolong the lives of patients with an aggressive type of cancer called malignant pleural mesothelioma, many patients avoid the operation for fear it will degrade their quality of ...

Please provide your email address to receive an email when new articles are posted on . Previous studies investigated whether surgery may extend survival among patients with malignant pleural ...

Please provide your email address to receive an email when new articles are posted on . Surgery for managing complicated pleural space infections had better outcomes than fibrinolytic therapy, ...

"Pleural effusion is a common complication after bypass surgery", say researchers who recently carried out a study of 400 patients who had undergone bypass heart surgery. Pleural effusion involves the ...

The median survival of patients undergoing trimodality therapy is 1–2 years, but some patients (19%) can live for 3–14 years. To improve outcomes and survival, the focus of clinical research over the ...